Cécile Brachet

Cécile Brachet

Auto-generated profile, based on publicly available information

Cécile Brachet

Pediatric Endocrinology Unit, Hôpital Universitaire des Enfants Reine Fabiola-ULB, Brussels, Belgium

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2015 in Human Reproduction
Verified
Journal Article
Open access
PDF file
IDIsabelle Demeestere
Isabelle Demeestere
PSPhilippe Simon
Philippe Simon
LDLaurence Dedeken
Laurence Dedeken
FMFederica Moffa
Federica Moffa
STSophie Tsépélidis
Sophie Tsépélidis
AFAlina Ferster
Alina Ferster
Ovarian insufficiency is a major long-term adverse event, following the administration of a myeloablative conditioning regimen, and occurring in >80% of children and adolescents receiving such treatment for malignant or non-malignant disease. Cryopreservation of ovarian tissue is currently offered to preserve the fertility of these young patients. At least 35 live births have been reported after transplantation of cryopreserved ovarian tissue in adult patients, but the procedure remains unproven for ovarian tissue harvested at a prepubertal or pubertal age. We report here the first live birth after autograft of cryopreserved ovarian tissue in a woman with primary ovarian failure after a myeloablative conditioning regimen as part of a hematopoietic stem cell transplantation performed for homozygous sickle-cell anemia at age 14 years. This first report of successful fertility restoration after the graft of ovarian tissue cryopreserved before menarche offers reassuring evidence for the feasibility of the procedure when performed during childhood.

5 March 2004 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
PBP. A. Brogan
P. A. Brogan
VSV. Shah
V. Shah
CBC. Brachet
C. Brachet
AHA. Harnden
A. Harnden
DMD. Mant
D. Mant
MDM. J. Dillon
M. J. Dillon
Objective: Microparticles are released from endothelial cells in response to a variety of injurious stimuli and recently have been shown to be increased in a number of diseases associated with endothelial dysfunction. This study examined endothelial microparticle (EMP) and platelet microparticle (PMP) profiles in children with systemic vasculitis to test the hypothesis that EMPs may provide a noninvasive means of examining endothelial activation or injury.Methods: The study cohort comprised 39 children with systemic vasculitis at various stages of disease activity, 24 control children with febrile disease, and a control group of 43 healthy subjects. Plasma was ultracentrifuged at 17,000g for 60 minutes, and the microparticle pellets were examined using flow cytometry.Results: Plasma from patients with active systemic vasculitis contained significantly higher numbers of E‐selectin–positive EMPs compared with that from patients in remission, healthy controls, or febrile disease controls (P = 0.000 for each). A similar result was obtained for the numbers of EMPs expressing the marker CD105. There was also a significant increase in PMPs expressing CD42a in the active vasculitis group as compared with the other groups, but this difference was not significant for PMPs expressing P‐selectin. The EMP counts correlated with the Birmingham Vasculitis Activity Score and the acute‐phase reactant levels in the patients with systemic vasculitis, but there was a poor correlation overall between EMP counts and the acute‐phase reactant levels in the febrile disease controls.Conclusion: EMPs may provide a window to the activated endothelium and could provide important pathophysiologic insights into the vascular injury associated with vasculitis of the young.

1 June 2022 in European Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
Anna NordenstromAnna Nordenstrom
Anna Nordenstrom
SASyed Faisal Ahmed
Syed Faisal Ahmed
EAE van Den Akker
E van Den Akker
JBJ Blair
J Blair
MBMarco Bonomi
Marco Bonomi
ODO M Dekkers
O M Dekkers
An Endo-European Reference Network guideline initiative was launched including 16 clinicians experienced in endocrinology, pediatric and adult and 2 patient representatives. The guideline was endorsed by the European Society for Pediatric Endocrinology, the European Society for Endocrinology and the European Academy of Andrology. The aim was to create practice guidelines for clinical assessment and puberty induction in individuals with congenital pituitary or gonadal hormone deficiency. A systematic literature search was conducted, and the evidence was graded according to the Grading of Recommendations, Assessment, Development and Evaluation system. If the evidence was insufficient or lacking, then the conclusions were based on expert opinion. The guideline includes recommendations for puberty induction with oestrogen or testosterone. Publications on the induction of puberty with follicle-stimulation hormone and human chorionic gonadotrophin in hypogonadotropic hypogonadism are reviewed. Specific issues in individuals with Klinefelter syndrome or androgen insensitivity syndrome are considered. The expert panel recommends that pubertal induction or sex hormone replacement to sustain puberty should be cared for by a multidisciplinary team. Children with a known condition should be followed from the age of 8 years for girls and 9 years for boys. Puberty induction should be individualised but considered at 11 years in girls and 12 years in boys. Psychological aspects of puberty and fertility issues are especially important to address in individuals with sex development disorders or congenital pituitary deficiencies. The transition of these young adults highlights the importance of a multidisciplinary approach, to discuss both medical issues and social and psychological issues that arise in the context of these chronic conditions.

16 January 2014 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
LDLaurence Dedeken
Laurence Dedeken
PLPhu Q. Lê
Phu Q. Lê
NANadira Azzi
Nadira Azzi
CBCécile Brachet
Cécile Brachet
CHCatherine Heijmans
Catherine Heijmans
AFAlina Ferster
Alina Ferster

1 July 2007 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
CBCécile Brachet
Cécile Brachet
CHClaudine Heinrichs
Claudine Heinrichs
STSylvie Tenoutasse
Sylvie Tenoutasse
CDChristine Devalck
Christine Devalck
NANadira Azzi
Nadira Azzi
AFAlina Ferster
Alina Ferster
The aim of this study is to describe the growth, pubertal development, and gonadal function of a cohort of 30 sickle cell disease children who underwent bone marrow transplantation. They all received the standard pretransplant conditioning regimen of busulfan (14 or 16 mg/kg) and cyclophosphamide (200 mg/kg). Growth was normal both before and after transplant. Seven out of 10 girls had severe ovarian failure and requirement for estrogen replacement. Three out of 10 girls recovered some ovarian function posttransplant, with spontaneous pubertal development, menses, and 1 successful normal pregnancy. Follicle-stimulating hormone (FSH) serum levels were very high during spontaneous puberty and slowly normalized thereafter in these 3 patients. The 3 girls with ovarian function recovery differed from the 7 others by the lower busulphan dose of the conditioning regimen they received (14 rather than 16 mg/kg). All boys showed spontaneous pubertal development. However, most of them had small testis and elevated serum FSH levels, reflecting germinal epithelium damage. Testosterone level was low normal and luteinizing hormone elevated, reflecting Leydig cell insufficiency. In conclusion, 7/10 girls had complete gonadal failure and most of the boys had spontaneous puberty but germinal epithelial failure. Serum FSH levels showed important variations over time in the same patient.

1 August 2016 in The American Journal of Human Genetics
Verified
Journal Article
Open access
FCFrauke Coppieters
Frauke Coppieters
GAGiulia Ascari
Giulia Ascari
KDKatharina Dannhausen
Katharina Dannhausen
KNKonstantinos Nikopoulos
Konstantinos Nikopoulos
FPFrank Peelman
Frank Peelman
Elfride De BaereElfride De Baere
Elfride De Baere
Inherited retinal dystrophies (iRDs) are a group of genetically and clinically heterogeneous conditions resulting from mutations in over 250 genes. Here, homozygosity mapping and whole-exome sequencing (WES) in a consanguineous family revealed a homozygous missense mutation, c.973C>T (p.His325Tyr), in RCBTB1. In affected individuals, it was found to segregate with retinitis pigmentosa (RP), goiter, primary ovarian insufficiency, and mild intellectual disability. Subsequent analysis of WES data in different cohorts uncovered four additional homozygous missense mutations in five unrelated families in whom iRD segregates with or without syndromic features. Ocular phenotypes ranged from typical RP starting in the second decade to chorioretinal dystrophy with a later age of onset. The five missense mutations affect highly conserved residues either in the sixth repeat of the RCC1 domain or in the BTB1 domain. A founder haplotype was identified for mutation c.919G>A (p.Val307Met), occurring in two families of Mediterranean origin. We showed ubiquitous mRNA expression of RCBTB1 and demonstrated predominant RCBTB1 localization in human inner retina. RCBTB1 was very recently shown to be involved in ubiquitination, more specifically as a CUL3 substrate adaptor. Therefore, the effect on different components of the CUL3 and NFE2L2 (NRF2) pathway was assessed in affected individuals' lymphocytes, revealing decreased mRNA expression of NFE2L2 and several NFE2L2 target genes. In conclusion, our study puts forward mutations in RCBTB1 as a cause of autosomal-recessive non-syndromic and syndromic iRD. Finally, our data support a role for impaired ubiquitination in the pathogenetic mechanism of RCBTB1 mutations.